GlassScriptPhysician profile
Ana Van Der Wall
NPI 1265672018
$8,687.94
in general payments reported to CMS, 2019-2025
65 companies · $2,506 in 2025
The $2,506 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $916 · 2021: $1,479 · 2022: $820 · 2023: $1,206 · 2024: $1,308 · 2025: $2,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,995 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,995.26 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $914.20 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $622.58 | 2020-2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $609.89 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $495.06 | 2019-2025 | |
| Daiichi Sankyo INC. | $391.94 | 2021-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $354.98 | 2019-2025 | |
| Gilead Sciences, INC. | $331.35 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $319.05 | 2020-2025 | Enhertu, Calquence |
| Janssen Biotech, INC. | $309.75 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Genzyme Corporation | $301.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $244.82 | 2022-2025 | Fruzaqla, Vpriv |
| Astellas Pharma US INC | $237.41 | 2019-2024 | Padcev, Xospata |
| Amgen INC. | $219.37 | 2019-2025 | Evenity |
| Abbvie INC. | $212.95 | 2020-2025 | Epkinly |
| Kite Pharma, INC. | $211.96 | 2020-2025 | Yescarta |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Van Der Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.